Debray H, Guihard J, Peyramond D, Tron P
Service de Pédiatrie, Hôpital Saint-Joseph, Paris.
Ann Pediatr (Paris). 1990 Dec;37(10):683-7.
The effectiveness and tolerance of alizapride and metopimazine used to treat vomiting induced by acute infectious diseases were evaluated in 47 infants and children seen in five hospitals. Patients were randomized to alizapride (n = 23) or metopimazine (n = 24). Medications were given orally (drops) for 3 to 5 days. All the patients were monitored until the end of the study period. Effectiveness was excellent or good in both groups with no statistically significant difference. Clinical tolerance was outstanding in both groups; one patient in the alizapride group exhibited transient, mild drowsiness after the doses. This study confirms the good risk/benefit ratio of alizapride in the treatment of emesis in infants and children.
在五家医院就诊的47名婴幼儿中评估了阿立必利和甲哌氯丙嗪治疗急性传染病所致呕吐的有效性和耐受性。患者被随机分为阿立必利组（n = 23）或甲哌氯丙嗪组（n = 24）。药物口服（滴剂）3至5天。对所有患者进行监测直至研究期结束。两组的有效性均为优或良，无统计学显著差异。两组的临床耐受性均良好；阿立必利组有1例患者在用药后出现短暂、轻度嗜睡。本研究证实了阿立必利治疗婴幼儿呕吐的良好风险/效益比。
